Like Leigh syndrome and DOA, MTRFR deficiencies are a good candidate for gene therapy treatment, and our studies have shown that we are able to get adequate expression in various organs without adverse effects of the MTRFR transgenes. Here, MTRFR is linked to autosomal dominant optic atrophy.